Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8300104 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Sulfuric Acid SCHEMBL6260312 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Sulfuric Acid SCHEMBL6099988 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Sulfuric Acid SCHEMBL8291975 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Piperazine SCHEMBL5875243 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Piperazine SCHEMBL27978492 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Piperazine SCHEMBL2445779 | 1.00 | TSHR (0.50) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Piperazine SCHEMBL30708072 | 0.96 | TSHR (0.48) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Piperazine SCHEMBL30517943 | 0.96 | TSHR (0.48) | TSHRCA5ACA5BGABRA1GABRG2 | |
| Sulfuric Acid SCHEMBL4097784 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5702804-A | Recording sheets | XEROX CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-4087621-A1 | MACROCYCLIC CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-11-16 | — | — | EP | disclosed |
| US-20210395281-A1 | MACROCYCLIC CHELATES AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-6995247-B2 | Ac-HEHA and related compounds, methods of synthesis and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040184991-A1 | Ac-HEHA and related compounds, methods of synthesis and methods of use | THE GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DPT. OF HEALTH AND HUMAN SERVICES | 2004-09-23 | — | — | US | disclosed |
| US-6696551-B1 | RADIOIMMUNOTHERAPY, DECONTAMINATION AND DETOXIFICATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-02-24 | — | — | US | disclosed |
| US-20030190530-A1 | Lithium Secondary Battery | NGK INSULATORS, LTD. (JP) | 2003-10-09 | — | — | US | disclosed |
| WO-1997004308-A1 | BUFFER/ADDITIVES ELECTROLYTE COMBINATIONS FOR ELECTROKINETIC CHROMATOGRAPHY | WATERS INVESTMENTS LIMITED (US) | 1997-02-06 | — | — | WO | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0425577-A1 | MACROCYCLIC ORGANIC POLYPHOSPHONATES | SOLVAY INTEROX LIMITED (GB) | 1991-05-08 | — | — | EP | disclosed |
| WO-1990001034-A1 | MACROCYCLIC ORGANIC POLYPHOSPHONATES | INTEROX CHEMICALS LIMITED (GB) | 1990-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040184991-A1 | Ac-HEHA and related compounds, methods of synthesis and methods of use | APEH, DOHH, DDAH1 | TSHR 741/4885CA5A 178/4885CA5B 309/4885 |
| US-20210395281-A1 | MACROCYCLIC CHELATES AND USES THEREOF | PAICS, CLTC, CLTB | TSHR 1623/4885CA5A 610/4885CA5B 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.